TABLE 4.
Toxicity assessment (n = 49)
| Toxicity | No. of patients of different Grade (CTCAE 4.0) | ||||
|---|---|---|---|---|---|
| 1 | 2 | 3 | 4 | 3/4% | |
| Anemia | 30 | 8 | 10 | 1 | 22.4 |
| Leukopenia | 22 | 18 | 9 | 0 | 18.4 |
| Neutropenia | 13 | 16 | 16 | 4 | 40.8 |
| Thrombocytopenia | 40 | 6 | 3 | 0 | 6.1 |
| Liver Function | |||||
| Bilirubin | 47 | 0 | 0 | 0 | 0 |
| ALT | 47 | 0 | 0 | 0 | 0 |
| AST | 47 | 0 | 0 | 0 | 0 |
| Anorexia | 28 | 17 | 4 | 0 | 8.2 |
| Nausea | 21 | 21 | 7 | 0 | 14.3 |
| Vomiting | 26 | 19 | 4 | 0 | 8.2 |
| Abdominal pain | 30 | 15 | 2 | 2 | 8.2 |
| Diarrhea | 35 | 8 | 6 | 0 | 12.2 |
| Constipation | 46 | 3 | 0 | 0 | 0 |
| Peripheral sensory neuropathy | 43 | 5 | 1 | 0 | 2.0 |
| Alopecia | 40 | 6 | 3 | 0 | 6.1 |
| Rash maculopapular | 46 | 3 | 0 | 0 | 0 |
| Fatigue | 28 | 18 | 3 | 0 | 6.1 |
Abbreviations: ALT, alanine transaminase; AST, glutamic‐oxaloacetic transaminase; CTCAE, Common Terminology Criteria for Adverse Events.